Advanced Technology Laboratories
This article was originally published in The Gray Sheet
Executive Summary
Premarket approval application for use of ATL's High Definition Imaging ultrasound system for distinguishing benign from malignant breast disease is filed by FDA and granted expedited review, Chairman and CEO Dennis Fill reports at a May 9 session of the Alex. Brown & Sons health care seminar in Baltimore. ATL submitted the PMA in February ("The Gray Sheet" Feb. 21, In Brief)